These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18473952)

  • 21. Diabetes and advanced glycation endproducts.
    Vlassara H; Palace MR
    J Intern Med; 2002 Feb; 251(2):87-101. PubMed ID: 11905595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic nephropathy and advanced glycation end products.
    Menè P; Festuccia F; Polci R; Pugliese F; Cinotti GA
    Contrib Nephrol; 2001; (131):22-32. PubMed ID: 11125560
    [No Abstract]   [Full Text] [Related]  

  • 23. Advanced glycation endproducts and diabetes. Beyond vascular complications.
    Puddu A; Viviani GL
    Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):132-40. PubMed ID: 21476962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.
    Neviere R; Yu Y; Wang L; Tessier F; Boulanger E
    Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes.
    Coughlan MT; Forbes JM; Cooper ME
    Kidney Int Suppl; 2007 Aug; (106):S54-60. PubMed ID: 17653212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
    Jandeleit-Dahm KA; Lassila M; Allen TJ
    Ann N Y Acad Sci; 2005 Jun; 1043():759-66. PubMed ID: 16037303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced glycation end-products: a review.
    Singh R; Barden A; Mori T; Beilin L
    Diabetologia; 2001 Feb; 44(2):129-46. PubMed ID: 11270668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RAGE: a novel target for drug intervention in diabetic vascular disease.
    Hudson BI; Schmidt AM
    Pharm Res; 2004 Jul; 21(7):1079-86. PubMed ID: 15290845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy.
    Wendt T; Tanji N; Guo J; Hudson BI; Bierhaus A; Ramasamy R; Arnold B; Nawroth PP; Yan SF; D'Agati V; Schmidt AM
    J Am Soc Nephrol; 2003 May; 14(5):1383-95. PubMed ID: 12707408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced glycation end products.
    Thomas MC
    Contrib Nephrol; 2011; 170():66-74. PubMed ID: 21659759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis of diabetic nephropathy: a radical approach.
    Salahudeen AK; Kanji V; Reckelhoff JF; Schmidt AM
    Nephrol Dial Transplant; 1997 Apr; 12(4):664-8. PubMed ID: 9140991
    [No Abstract]   [Full Text] [Related]  

  • 32. [The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications].
    Barbosa JH; Oliveira SL; Seara LT
    Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):940-50. PubMed ID: 18820805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of AGEs in diabetic nephropathy.
    Fukami K; Yamagishi S; Ueda S; Okuda S
    Curr Pharm Des; 2008; 14(10):946-52. PubMed ID: 18473844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics.
    Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE
    Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Advanced glycation end products and hyperglycaemia].
    Omsland TK; Bangstad HJ; Berg TJ; Kolset SO
    Tidsskr Nor Laegeforen; 2006 Jan; 126(2):155-8. PubMed ID: 16415936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
    Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
    Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advanced glycation endproducts in diabetes and diabetic complications.
    Vlassara H; Striker GE
    Endocrinol Metab Clin North Am; 2013 Dec; 42(4):697-719. PubMed ID: 24286947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
    Yamagishi S; Taguchi K; Fukami K
    Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy.
    Kumar Pasupulati A; Chitra PS; Reddy GB
    Biomol Concepts; 2016 Dec; 7(5-6):293-309. PubMed ID: 27816946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced glycation end products (AGEs) and their receptor (RAGE) in health and disease.
    Yamagishi S
    Curr Pharm Des; 2008; 14(10):939. PubMed ID: 18473842
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.